Medicare Advantage
  
  
  
  
  
  
  
  
  
  
  
  
MPattachmentdataPub
  
09717c45-059c-488a-8eb1-95bcf1c67b3b.aspx
  
2930Prostate Mapping BiopsySurgery (11)MA11.016aMA11.01609717c45-059c-488a-8eb1-95bcf1c67b3bProstate Mapping BiopsyProstate Mapping Biopsy9/10/2021 11:00 AM
728729be-bc72-4a2f-b680-55ad4c00589d.aspx
  
2923RadiationTherapyServicesMA09.020mRadiology (09)MA09.020mMA09.020728729be-bc72-4a2f-b680-55ad4c00589dRadiation Therapy ServicesRadiation Therapy Services8/31/2021 10:00 AM
{"2924": {"Id":2924,"MPAttachmentLetter":"A","Title":"CPT, HCPCS and Revenue Codes","MPPolicyAttachmentInternalSourceId":5686,"PolicyAttachmentPageName":"f125861f-df8d-4ad5-a856-50dbd1c417f4"},}
10/1/2021
5fa0dc63-069a-4b61-9acb-d1500921a9ab.aspx
  
2840Interleukin-5(IL-5)Antagonist(e.g.,Cinqair®,Nucala®)andIL-5ReceptorAntagonist(e.g.,Fasenra®)MA08.024iPharmacy (08)MA08.024iMA08.0245fa0dc63-069a-4b61-9acb-d1500921a9abInterleukin-5 (IL-5) Antagonist (e.g., Cinqair®, Nucala®) and IL-5 Receptor Antagonist (e.g., Fasenra®)Interleukin-5 (IL-5) Antagonist (e.g., Cinqair®, Nucala®) and IL-5 Receptor Antagonist (e.g., Fasenra®)7/6/2021 1:00 PM
10/4/2021
b3e3245b-4a38-44e5-ac62-456810c3f0fd.aspx
  
2879Omalizumab(Xolair®)MA08.025dPharmacy (08)MA08.025dMA08.025b3e3245b-4a38-44e5-ac62-456810c3f0fdOmalizumab (Xolair®)Omalizumab (Xolair®)7/6/2021 1:00 PM
{"2880": {"Id":2880,"MPAttachmentLetter":"A","Title":"Dosing and Frequency Requirements for Omalizumab (Xolair®)","MPPolicyAttachmentInternalSourceId":5481,"PolicyAttachmentPageName":"cb7623d5-6267-4e8e-8564-5d7958cad63b"},}
10/4/2021
7255d69f-cc1f-4af2-968d-a2f346768f25.aspx
  
2941UltravioletLightTherapyfortheTreatmentofDermatologicalConditionsMA07.002eMedicine (07)MA07.002eMA07.0027255d69f-cc1f-4af2-968d-a2f346768f25Ultraviolet Light Therapy for the Treatment of Dermatological ConditionsUltraviolet Light Therapy for the Treatment of Dermatological Conditions8/13/2021 2:00 PM
{"2942": {"Id":2942,"MPAttachmentLetter":"A","Title":"ICD-10-CM codes","MPPolicyAttachmentInternalSourceId":5674,"PolicyAttachmentPageName":"12e9b9e1-85f5-4d2b-8d33-19a7a95bfd91"},}
11/15/2021
b1491700-d5fe-4a16-bf16-ccdc067ce04b.aspx
  
2902TreatmentofPulmonaryArteryHypertensionwithIntravenous,Subcutaneous,andInhaledPharmacologicAgentsMA08.016fPharmacy (08)MA08.016fMA08.016b1491700-d5fe-4a16-bf16-ccdc067ce04bTreatment of Pulmonary Artery Hypertension with Intravenous, Subcutaneous, and Inhaled Pharmacologic AgentsTreatment of Pulmonary Artery Hypertension with Intravenous, Subcutaneous, and Inhaled Pharmacologic Agents8/18/2021 11:00 AM
{"2903": {"Id":2903,"MPAttachmentLetter":"A","Title":"Dosing and Frequency Requirements","MPPolicyAttachmentInternalSourceId":5448,"PolicyAttachmentPageName":"c9bb97f1-7118-4084-b97b-adf9c5f10770"},}
11/22/2021